Drug Discovery Outsourcing Market by Workflow, Therapeutics Area, Drug Type, Service Type, End-user & Region | Forecast 2023 to 2033
AI-based Method Enables Cruelty-free, Fast, and Reliable Drug Discovery and Development Procedures. FMI Explores how Outsourcing in Drug Discovery Process Reduces Biomedical Costs.
The drug discovery outsourcing market is expected to expand its roots at a steady CAGR of 7.2% during the forecast period. The market is likely to hold a revenue of US$ 3.75 billion in 2023, while it is anticipated to cross a value of US$ 7.52 billion by 2033.
The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs. The higher penetration of smart technology in the drug discovery and development process is likely to transform the market condition. Furthermore, AI drug discovery outsourcing is much cheaper, easy, and integrated. Thus, pharmaceutical brands adopt these newly designed methods to increase reliability and promote cruelty-free discovery. Alongside this, the growing outsourcing trend in Asian economies like India and China is likely to strengthen the pharmaceutical ties between the West and East. The wave of novel drug discovery in India, with brands building their projects around the Indian drug discovery outsourcing space, is anticipated to flourish the market growth. Moreover, the government projects and the bilateral relationship are also anticipated to increase drug production. This pushes pharma companies to look for biomedical advancements.
The market dynamics have been affected by the pandemic, the geriatric population, and new diseases spreading out of nations. Thus, the consumption of advanced drugs, drug mixtures (synergistic drugs), and other anti-infection drugs are likely to put pressure on the brands. This leads pharmaceutical companies to reach out to distant markets to reduce the cost of production and research of drug discovery and development.
The use of stimulating organs coupled with organs-on-chips for disease modeling and drug development is likely to change the market dynamic. From hit confirmation to lead optimization and high-speed screening services, the smart tech has reformed each component of the drug discovery systems. An estimate states that 80% of the research for different pharmaceutical elements can be outsourced. Thus, the drug discovery outsourcing market is likely to garner during the forecast period.
Attributes
Details
Drug Discovery Outsourcing Market CAGR (2023 to 2033)
7.2%
Drug Discovery Outsourcing Market Size (2023)
US$ 3.75 billion
Drug Discovery Outsourcing Market Size (2033)
US$ 7.52 billion
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How is the Future Outlook (2023 to 2033) for Drug Discovery Outsourcing Market in Comparison to the Historical Pattern (2018 to 2022)?
According to FMI analysis, the drug discovery outsourcing market was valued at US$ 3.50 billion in 2022 and is likely to be worth US$ 7.52 billion by 2033.
Short-term Growth (2023 to 2026): This period is expected to be game-changing for the outsourcing market. It is due to the technology and healthcare outsourcing business expansion in Asian economies along with some African states. Furthermore, the government projects under bilateral ties to tackle future healthcare calamities also add value to the market growth. Hence, the market is expected to hold US$ 3.75 billion in 2023, while it is likely to reach US$ 4.62 billion by 2026.
Mid-term Growth (2026 to 2029): During the projected period, a primary factor that drives the demand for drug discovery outsourcing services is the surge in new diseases. The new technology is integrated into the expanding smart technologies such as artificial intelligence and advanced healthcare communication. This takes a market value from US$ 4.62 billion in 2026 to US$ 5.69 billion in 2029.
Long-term Growth (2029 to 2033): The cheaper research outsourcing and higher demand for new drugs for specific diseases. Pharmaceutical companies collaborate with production factories in emerging economies with high populations and cheap workforces. This period is anticipated to witness steady growth. Thus, the drug discovery outsourcing market is anticipated to thrive at a steady CAGR of 7.2% between 2023 and 2033.
What Growth Drivers Flourish the Drug Discovery Outsourcing Market?
AI-enabled drug discovery methods, along with the expanding research and development programs, are garnering market growth. The increased penetration of innovation, reduced costs, and pharmaceutical companies collaborating for the research part fuel the market growth.
The application of AI in protein modeling, digital organ simulation, and organ-on-a-chip is also easing the drug discovery process. Developing nations like India and China are becoming the center stage for the pharmaceutical revolution with mass drug production and extended research and development programs. The AI-driven drug discovery is anticipated to increase the capital investment in distant lands to expand their production and research workforce. Alongside this, the new AI drug discovery outsourcing services are likely to enhance target identification, patient stratification, and biomarker development.
As COVID-19 pandemic garnered the pharmaceutical industry, new viruses and their penetration in developed nations are also increasing drug consumption. Even developing nations enhancing public health conditions are adopting advanced drug discovery measures. Similarly, they are indulged in collaborating with cheaper third-party research and development vendors.
Find your sweet spots for generating winning opportunities in this market.
What are the Key Restraints in the Drug Discovery Outsourcing Market?
Key restraints for the drug discovery outsourcing market are governmental restrictions, higher outsourcing costs, and tariffs restraining market growth. The rapidly expanding space for alternative medicine and limited medical budgets are limiting the growth of the market.
Comparative View of the Adjacent Market
Drug Discovery Outsourcing Market:
Attributes
Drug Discovery Outsourcing Market
CAGR (2023 to 2033)
7.2%
Market Value (2033)
US$ 7.52 billion
Growth Factor
The expanding pharmaceutical business along with the integration of artificial intelligence and cheaper research force is fuelling the market growth.
Opportunity
Pharmaceutical companies collaborating with distant outsourcing vendors are also bringing new opportunities to the market.
Key Trends
The new developing infectious diseases (ID) drugs and vaccines are shaping new trends in the market.
Pharmaceutical Drug Delivery Market:
Attributes
Pharmaceutical Drug Delivery Market
CAGR (2023 to 2033)
5.8%
Market Value (2033)
US$ 3.25 billion
Growth Factor
The rise in chronic diseases, expanding biologics market, and increasing research and development facilities are increasing the pharmaceutical drug delivery market.
Opportunity
The latest technological advancements such as AI integration and healthcare digitization create new opportunities for the market.
Key Trends
Disease-specific drug delivery solutions are shaping the new trends in the market.
Transdermal Drug Market:
Attributes
Transdermal Drug Market
CAGR (2023 to 2033)
11.8%
Market Value (2033)
US$ 202.60 billion
Growth Factor
The high potency, improved hepatic first-pass metabolism, and expanding pharmaceutical industry are anticipated to fuel the sales of transdermal drug delivery systems.
Opportunity
Technological advancements such as microneedles or mechanical arrays in transdermal patches are expected to bring new opportunities for the market.
Key Trends
The pain-free and cruelty-free transdermal drug delivery system is shaping the trends in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
Why is the United States Considered a Lucrative Market for Drug Discovery Outsourcing?
Increased Demand for Research and Development along with Expanding Bilateral Ties are making North America the Top Growing Region
North America region leads in terms of the market share in the drug discovery outsourcing market with a market share CAGR of 35.5%. The growth is attributed to lower research costs, higher innovative experiments, and increasing demand for generic and disease-specific drugs. Furthermore, companies collaborating with third-party drug discovery service vendors are likely to impact the market positively. The rising competition is fueled by factors such as higher efficiency, quality, and innovation is garnering regional growth.
How does Japan perform in Drug Discovery Outsourcing Market?
Integration of Smart Technologies coupled with Heavy Demand for Generic Medicine is Fuelling the Demand for Drug Discovery Outsourcing
Asia Pacific region leads the market in terms of CAGR between 2023 and 2033. Japan drug discovery outsourcing markets in the Asia Pacific region. Apart from the higher population and higher investment, the Japanese market comes in the pharmaceutical market due to smart technology integration. The AI-enabled drug discovery method is transforming the industry with fast, reliable, inexpensive, and cruelty-free drug discovery.
What makes the United Kingdom another significant market for Drug Discovery Outsourcing Market?
Concepts like Digital Organ Simulation and Organ-on-a-chip are collectively flourishing the Regional Growth
The United Kingdom is another significant market for drug discovery outsourcing systems. The increase in virus mutations and deadly chronic diseases is pushing the demand for drug discovery outsourcing. Better prediction in human drug discovery also impacts the various treatment garnering market growth.
Category-wise Landscape
Category
By Workflow
Leading Segment
Lead Identification & Candidate Optimization
Market Share % (2022)
32.3%
Category
By Therapeutic Area
Leading Segment
Respiratory Systems
Market Share % (2022)
14%
Higher Activity, Increase Selectivity, and Reduced Side Effects are Garnering the Segmental Growth
Based on the workflow, lead identification & candidate optimization held the leading share of 32.3% in 2022. The growth is attributed to better workflow management. Also, increased activity around the non-bonded interaction and reduced side effects are making this segment more popular in the category. It is expected to improve potency and dynamics as well.
Increased Respiratory Diseases post Pandemic along with the Therapeutic Effects are Propelling the Segment’s Growth
Based on the therapeutic area, the respiratory systems segment held a share of 14.0% in 2022. The higher amount of chronic diseases impacting the respiratory organs and developing various chronic and non-chronic diseases are thriving segmental growth. The therapeutic areas involve oncology, ophthalmology, hematology, cardiovascular, endocrine, and others. The diseases like bronchitis, tuberculosis, COPD, and asthma fuel the segment growth.
Competition Scenario
The key players focus on adopting advanced AI-enabled drug discovery outsourcing services. The end users choose the vendors that not only provide better pricing but also efficient quality and timing. Companies also merge, collaborate, and acquire in order to expand their sales and distributional channels.
Market Developments
EVOTEC has introduced different discovery options for antibody discovery such as integrated drug discovery, integrated CMC, integrated pre-clinical, target ID, and validation services.
The Genscript has launched small-molecule drugs and large-molecule drug discovery programs that use organic or metallic compounds.
Key Players
Albany Molecular Research Inc.
EVOTEC
Laboratory Corporation of America Holdings
GenScript
Pharmaceutical Product Development, LLC
Charles River
WuXi AppTec
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Dalton Pharma Services
Oncodesign
Jubilant Biosys
DiscoverX Corp.
QIAGEN
Eurofins SE
Syngene International Limited
Dr. Reddy Laboratories Ltd.
Pharmaron Beijing Co., Ltd.
TCG Lifesciences Pvt Ltd.
Domainex Ltd.
Market Segmentation
Workflow Outlook:
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Other Associated Workflow
Therapeutics Area Outlook:
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-infective
Central Nervous System
Dermatology
Genitourinary System
Drug Type Outlook:
Small Molecules
Large Molecules (Biopharmaceuticals)
Service Type Outlook:
Chemistry Services
Biology Services
End-user Outlook:
Pharmaceutical & Biotechnology companies
Academic Institutes
Others
Key Regions Covered:
North America
United States
Canada
Latin America
Brazil
Mexico
Rest of Latin America
Europe
Germany
United Kingdom
France
Spain
Russia
Rest of Europe
Japan
Asia Pacific Excluding Japan
China
India
Malaysia
Singapore
Australia
Rest of Asia Pacific Excluding Japan (APEJ)
The Middle East and Africa
GCC Countries
Israel
South Africa
Rest of Middle East Asia (MEA)
Frequently Asked Questions
The drug discovery outsourcing market is valued at US$ 3.75 billion in 2023.
Albany Molecular Research Inc., EVOTEC and Laboratory Corporation of America Holdings are key players.
The drug discovery outsourcing market will reach US$ 7.52 billion by 2033.
AI-driven drug discovery, expanding R&D, innovation adoption, cost reduction, and pharma collaboration propel the market.
Lead Identification & Candidate Optimization segment to remain preferred in the market through 2033.
Table of Content
1. Executive Summary | Drug Discovery Outsourcing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Workflow, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Workflow, 2023 to 2033
5.3.1. Target Identification & Screening
5.3.2. Target Validation & Functional Informatics
5.3.3. Lead Identification & Candidate Optimization
5.3.4. Preclinical Development
5.3.5. Other Associated Workflow
5.4. Y-o-Y Growth Trend Analysis By Workflow, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Workflow, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics Area
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapeutics Area, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutics Area, 2023 to 2033
6.3.1. Respiratory system
6.3.2. Pain and Anaesthesia
6.3.3. Oncology
6.3.4. Ophthalmology
6.3.5. Haematology
6.3.6. Cardiovascular
6.3.7. Endocrine
6.3.8. Gastrointestinal
6.3.9. Immunomodulation
6.3.10. Dermatology
6.3.11. Central Nervous System
6.3.12. Genitourinary System
6.4. Y-o-Y Growth Trend Analysis By Therapeutics Area, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Therapeutics Area, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
7.3.1. Small Molecules
7.3.2. Large Molecules
7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
8.3.1. Pharmaceutical and Biotechnology companies
8.3.2. Academic Institutes
8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Workflow
10.2.3. By Therapeutics Area
10.2.4. By Drug Type
10.2.5. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Workflow
10.3.3. By Therapeutics Area
10.3.4. By Drug Type
10.3.5. By End User
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Workflow
11.2.3. By Therapeutics Area
11.2.4. By Drug Type
11.2.5. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Workflow
11.3.3. By Therapeutics Area
11.3.4. By Drug Type
11.3.5. By End User
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Workflow
12.2.3. By Therapeutics Area
12.2.4. By Drug Type
12.2.5. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Workflow
12.3.3. By Therapeutics Area
12.3.4. By Drug Type
12.3.5. By End User
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Workflow
13.2.3. By Therapeutics Area
13.2.4. By Drug Type
13.2.5. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Workflow
13.3.3. By Therapeutics Area
13.3.4. By Drug Type
13.3.5. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Workflow
14.2.3. By Therapeutics Area
14.2.4. By Drug Type
14.2.5. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Workflow
14.3.3. By Therapeutics Area
14.3.4. By Drug Type
14.3.5. By End User
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Workflow
15.2.3. By Therapeutics Area
15.2.4. By Drug Type
15.2.5. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Workflow
15.3.3. By Therapeutics Area
15.3.4. By Drug Type
15.3.5. By End User
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Workflow
16.2.3. By Therapeutics Area
16.2.4. By Drug Type
16.2.5. By End User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Workflow
16.3.3. By Therapeutics Area
16.3.4. By Drug Type
16.3.5. By End User
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Workflow
17.1.2.2. By Therapeutics Area
17.1.2.3. By Drug Type
17.1.2.4. By End User
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Workflow
17.2.2.2. By Therapeutics Area
17.2.2.3. By Drug Type
17.2.2.4. By End User
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Workflow
17.3.2.2. By Therapeutics Area
17.3.2.3. By Drug Type
17.3.2.4. By End User
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Workflow
17.4.2.2. By Therapeutics Area
17.4.2.3. By Drug Type
17.4.2.4. By End User
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Workflow
17.5.2.2. By Therapeutics Area
17.5.2.3. By Drug Type
17.5.2.4. By End User
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Workflow
17.6.2.2. By Therapeutics Area
17.6.2.3. By Drug Type
17.6.2.4. By End User
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Workflow
17.7.2.2. By Therapeutics Area
17.7.2.3. By Drug Type
17.7.2.4. By End User
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Workflow
17.8.2.2. By Therapeutics Area
17.8.2.3. By Drug Type
17.8.2.4. By End User
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Workflow
17.9.2.2. By Therapeutics Area
17.9.2.3. By Drug Type
17.9.2.4. By End User
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Workflow
17.10.2.2. By Therapeutics Area
17.10.2.3. By Drug Type
17.10.2.4. By End User
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Workflow
17.11.2.2. By Therapeutics Area
17.11.2.3. By Drug Type
17.11.2.4. By End User
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Workflow
17.12.2.2. By Therapeutics Area
17.12.2.3. By Drug Type
17.12.2.4. By End User
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Workflow
17.13.2.2. By Therapeutics Area
17.13.2.3. By Drug Type
17.13.2.4. By End User
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Workflow
17.14.2.2. By Therapeutics Area
17.14.2.3. By Drug Type
17.14.2.4. By End User
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Workflow
17.15.2.2. By Therapeutics Area
17.15.2.3. By Drug Type
17.15.2.4. By End User
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Workflow
17.16.2.2. By Therapeutics Area
17.16.2.3. By Drug Type
17.16.2.4. By End User
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Workflow
17.17.2.2. By Therapeutics Area
17.17.2.3. By Drug Type
17.17.2.4. By End User
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Workflow
17.18.2.2. By Therapeutics Area
17.18.2.3. By Drug Type
17.18.2.4. By End User
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Workflow
17.19.2.2. By Therapeutics Area
17.19.2.3. By Drug Type
17.19.2.4. By End User
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Workflow
17.20.2.2. By Therapeutics Area
17.20.2.3. By Drug Type
17.20.2.4. By End User
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Workflow
17.21.2.2. By Therapeutics Area
17.21.2.3. By Drug Type
17.21.2.4. By End User
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Workflow
18.3.3. By Therapeutics Area
18.3.4. By Drug Type
18.3.5. By End User
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Albany Molecular Research Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. EVOTEC
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Laboratory Corporation of America Holdings
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. GenScript
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pharmaceutical Product Development, LLC
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Merck & Co., Inc.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Thermo Fisher Scientific Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Dalton Pharma Services
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Dr. Reddy Laboratories Ltd.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Pharmaron Beijing Co., Ltd.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. TCG Lifesciences Pvt Ltd.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Domainex Ltd.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Eurofins SE
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Syngene International Limited
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 5: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 9: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 10: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 13: Latin America Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 14: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 15: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 18: Europe Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 19: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 20: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 23: South Asia Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 24: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 25: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 26: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 28: East Asia Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 29: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 30: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 31: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 33: Oceania Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 34: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 35: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 36: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: MEA Market Value (US$ Million) Forecast by Workflow, 2018 to 2033
Table 38: MEA Market Value (US$ Million) Forecast by Therapeutics Area, 2018 to 2033
Table 39: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 40: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 5: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 12: Global Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 15: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 18: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 21: Global Market Attractiveness by Workflow, 2023 to 2033
Figure 22: Global Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 23: Global Market Attractiveness by Drug Type, 2023 to 2033
Figure 24: Global Market Attractiveness by End User, 2023 to 2033
Figure 25: Global Market Attractiveness by Region, 2023 to 2033
Figure 26: North America Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 27: North America Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 28: North America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 29: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 30: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 37: North America Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 38: North America Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 39: North America Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 40: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 41: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 42: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 43: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 44: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 45: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 46: North America Market Attractiveness by Workflow, 2023 to 2033
Figure 47: North America Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 48: North America Market Attractiveness by Drug Type, 2023 to 2033
Figure 49: North America Market Attractiveness by End User, 2023 to 2033
Figure 50: North America Market Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 52: Latin America Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 53: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 55: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 62: Latin America Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 65: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 68: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 69: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 71: Latin America Market Attractiveness by Workflow, 2023 to 2033
Figure 72: Latin America Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 73: Latin America Market Attractiveness by Drug Type, 2023 to 2033
Figure 74: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 75: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 76: Europe Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 77: Europe Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 78: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 79: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 80: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 85: Europe Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 87: Europe Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 88: Europe Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 90: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 91: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 93: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 94: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 95: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 96: Europe Market Attractiveness by Workflow, 2023 to 2033
Figure 97: Europe Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 98: Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 99: Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 102: South Asia Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 103: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 104: South Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 105: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 112: South Asia Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 115: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 116: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 118: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 119: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 121: South Asia Market Attractiveness by Workflow, 2023 to 2033
Figure 122: South Asia Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 123: South Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 124: South Asia Market Attractiveness by End User, 2023 to 2033
Figure 125: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 127: East Asia Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 128: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 129: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 130: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 137: East Asia Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 140: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 141: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 143: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 144: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 146: East Asia Market Attractiveness by Workflow, 2023 to 2033
Figure 147: East Asia Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 148: East Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 149: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 150: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 152: Oceania Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 153: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 154: Oceania Market Value (US$ Million) by End User, 2023 to 2033
Figure 155: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 162: Oceania Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 165: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 166: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 168: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 169: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 171: Oceania Market Attractiveness by Workflow, 2023 to 2033
Figure 172: Oceania Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 173: Oceania Market Attractiveness by Drug Type, 2023 to 2033
Figure 174: Oceania Market Attractiveness by End User, 2023 to 2033
Figure 175: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 176: MEA Market Value (US$ Million) by Workflow, 2023 to 2033
Figure 177: MEA Market Value (US$ Million) by Therapeutics Area, 2023 to 2033
Figure 178: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 179: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 180: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 181: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: MEA Market Value (US$ Million) Analysis by Workflow, 2018 to 2033
Figure 185: MEA Market Value Share (%) and BPS Analysis by Workflow, 2023 to 2033
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Workflow, 2023 to 2033
Figure 187: MEA Market Value (US$ Million) Analysis by Therapeutics Area, 2018 to 2033
Figure 188: MEA Market Value Share (%) and BPS Analysis by Therapeutics Area, 2023 to 2033
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Therapeutics Area, 2023 to 2033
Figure 190: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 191: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 193: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 194: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 195: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 196: MEA Market Attractiveness by Workflow, 2023 to 2033
Figure 197: MEA Market Attractiveness by Therapeutics Area, 2023 to 2033
Figure 198: MEA Market Attractiveness by Drug Type, 2023 to 2033
Figure 199: MEA Market Attractiveness by End User, 2023 to 2033
Figure 200: MEA Market Attractiveness by Country, 2023 to 2033
